% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Konitsioti:1052365,
      author       = {Konitsioti, Agni M. and Grajewski, Rafael and Schlamann,
                      Mark and Schroeter, Michael and Fink, Gereon R. and Warnke,
                      Clemens},
      title        = {{S}uccessful {N}atalizumab {T}reatment of {T}wo {F}emale
                      {I}ndividuals {W}ith {S}usac {S}yndrome},
      journal      = {European journal of neurology},
      volume       = {32},
      number       = {3},
      issn         = {1351-5101},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {FZJ-2026-00963},
      pages        = {e70103},
      year         = {2025},
      note         = {Open Access funding enabled and organized by Projekt DEAL.},
      abstract     = {Background: Susac syndrome is a rare autoimmune
                      endotheliopathy that affects the central nervous system,
                      retina, and inner ear, characterized by encephalopathy,
                      branch retinal artery occlusions, and sensorineural hearing
                      loss. Due to the heterogeneity of its presentation, early
                      diagnosis, and treatment remain
                      challenging.Objective/methods: To evaluate the clinical
                      outcomes and radiological responses in two patients with
                      Susac syndrome treated with natalizumab in an off-label
                      therapeutic approach, clinical assessments and serial
                      magnetic resonance imaging (MRI) were performed over a
                      follow-up period of up to 22 months to monitor disease
                      progression and treatment response.Results: Both patients
                      demonstrated clinical stabilization with reduced MRI and
                      retinal angiography disease activity. Treatment was well
                      tolerated, and no significant adverse events were reported
                      during observation.Discussion: Natalizumab may constitute a
                      potential off-label therapeutic for Susac syndrome. Further
                      studies are warranted to assess its efficacy and safety in
                      this rare condition.Keywords: DMT; MRI; neuroimmunology;
                      neuroinflammation; neuroopthalmology; susac; vasculitis.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5251 - Multilevel Brain Organization and Variability
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5251},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1111/ene.70103},
      url          = {https://juser.fz-juelich.de/record/1052365},
}